Axsome Stock Surges 20% on Auvelity Patent Settlement With Teva
Portfolio Pulse from
Axsome Therapeutics' stock surged 20% following a settlement with Teva over the Auvelity patent, ensuring the drug's exclusivity in the U.S. until at least September 30, 2038.
February 11, 2025 | 2:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Axsome Therapeutics' stock rose by 20% after settling a patent dispute with Teva, securing exclusivity for its drug Auvelity in the U.S. until 2038.
The settlement with Teva removes a significant legal uncertainty for Axsome, securing the market exclusivity of its drug Auvelity in the U.S. This is a positive development for the company, likely leading to increased investor confidence and a rise in stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100